Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Next Previous
Trial Profile

A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Octreotide
  • Indications Carcinoid tumour; Coecal cancer; Gastro-enteropancreatic neuroendocrine tumour; Intestinal cancer; Paraganglioma; Phaeochromocytoma
  • Focus Registrational; Therapeutic Use
  • Acronyms NETTER-1
  • Sponsors Advanced Accelerator Applications

Most Recent Events

  • 03 Mar 2025 Results(n=20) of substudy assessing dosimetry of a standard 4-cycle protocol and any potential relationship to toxicity, published in the Journal of Nuclear Medicine.
  • 15 Nov 2021 final analysis of overall survival and long-term safety from NETTER-1 trial published in the Lancet Oncology
  • 03 Jul 2021 Final overall survival and long-term safety data presented at the 23rd World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top